尿道保留前列腺立体定向体部放疗单药与虚拟高剂量率近距离放疗推量的泌尿生殖生活质量比较
比较两项尿道保留SBRT试验中患者报告的EPIC-26泌尿生殖生活质量,单药组46例、推量组149例完成基线评分,单药组在12和36个月尿失禁与刺激性/梗阻症状均值更优,但各时间点最小临床重要变化比值无显著差异。
要点
- 单药组36.25 Gy/5次,推量组先19–21 Gy/2次推量再46 Gy/23次或36 Gy/12次。
- 单药组12个月尿失禁均值差6.9(95%CI 1.6–12.1,P=.01),36个月9.6(95%CI 4.1–15.1,P<.01)。
- 单药组12个月刺激性/梗阻均值差6.9(95%CI 2.0–12.9,P<.01),36个月6.3(95%CI 1.9–10.8,P<.01)。
核心结论
- 即使采用尿道保留,推量方案较高的BED可能对泌尿生殖生活质量有轻度不良影响,但未转化为最小临床重要变化比值上的统计学显著差异。
- 推量组较高BED是否带来疗效优势正在TROG 18.01 NINJA随机试验中研究。
研究设计与样本
- 比较两项尿道保留SBRT试验的EPIC-26泌尿生殖评分:SPARK单药组46例完成基线评分,PROMETHEUS推量组149例完成基线评分。
- 采用混合效应logistic回归模型估计各随访时点两组间从基线EPIC-26泌尿生殖评分发生最小临床重要变化的比值差异。
主要发现
- 单药组12个月尿失禁均值差6.9(95%CI 1.6–12.1,P=.01),36个月均值差9.6(95%CI 4.1–15.1,P<.01),均优于推量组。
- 单药组12个月刺激性/梗阻均值差6.9(95%CI 2.0–12.9,P<.01),36个月均值差6.3(95%CI 1.9–10.8,P<.01),均优于推量组。
- 两个领域所有时间点的绝对差异均<10%。
- 各时间点两组间报告最小临床重要变化的比值均无显著差异。
关键数值与推荐
- SPARK试验单药方案:36.25 Gy分5次照射前列腺。
- PROMETHEUS试验推量方案:分两阶段,先19–21 Gy分2次推量至前列腺,再46 Gy分23次或36 Gy分12次。
- 尿道毒性BED:单药组123.9 Gy,推量组155.8–171.2 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although radiation dose escalation improves prostate cancer disease control, it can cause increased toxicity. Genitourinary (GU) symptoms after prostate radiation therapy affect patient health-related quality of life (QoL). We compared patient-reported GU QoL outcomes following 2 alternative urethral sparing stereotactic body radiation therapy regimens. METHODS AND MATERIALS: Expanded Prostate Cancer Index Composite (EPIC)-26 GU scores were compared between 2 urethral sparing stereotactic body radiation therapy trials. The SPARK trial prescribed a "Monotherapy" dose of 36.25 Gy in 5 fractions to the prostate. The PROMETHEUS trial prescribed 2 phases: a 19- to 21-Gy in 2 fractions "Boost" to the prostate, followed by 46 Gy in 23 fractions or 36 Gy in 12 fractions. The biological effective dose (BED) for urethral toxicity was 123.9 Gy for Monotherapy and 155.8 to 171.2 Gy for Boost. Mixed effects logistic regression models were utilized to estimate the difference in the odds of a minimal clinically important change from baseline EPIC-26 GU score between regimens at each follow-up. RESULTS: 46 Monotherapy and 149 Boost patients completed baseline EPIC-26 scoring. Mean EPIC-26 GU scores revealed statistically superior urinary incontinence outcomes for Monotherapy at 12 months (mean difference, 6.9; 95% confidence interval [CI], 1.6-12.1; P = .01) and 36 months (mean difference, 9.6; 95% CI, 4.1-15.1; P < .01). Monotherapy also revealed superior mean urinary irritative/obstructive outcomes at 12 months (mean difference, 6.9; 95% CI, 2.0-12.9; P < .01) and 36 months (mean difference, 6.3; 95% CI, 1.9-10.8; P < .01). For both domains and at all time points, the absolute differences were <10%. There were no significant differences in the odds of reporting a minimal clinically important change between regimens at any time point. CONCLUSIONS: Even in the presence of urethral sparing, the higher BED delivered in the Boost schedule may have a small adverse effect on GU QoL compared with Monotherapy. However, this did not translate to statistically significant differences in minimal clinically important changes. Whether the higher BED of the boost arm offers an efficacy advantage is being investigated in the Trans Tasman Radiation Oncology Group 18.01 NINJA randomized trial.
引用
- Richardson M, Sidhom M, Keall P, et al. Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. Int J Radiat Oncol Biol Phys. 2023. PMID: 36889514. doi:10.1016/j.ijrobp.2023.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。